Botanix Pharmaceuticals Limited BXPHF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.96M | 18.55M | 14.25M | 8.95M | 3.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.96M | 18.55M | 14.25M | 8.95M | 3.68M |
| Cost of Revenue | 9.79M | 7.64M | 5.53M | 3.97M | 2.42M |
| Gross Profit | 13.16M | 10.91M | 8.72M | 4.99M | 1.26M |
| SG&A Expenses | 58.68M | 60.11M | 61.54M | 57.22M | 53.22M |
| Depreciation & Amortization | 1.57M | 1.54M | 1.50M | 1.48M | 1.47M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.05M | 69.29M | 68.57M | 62.66M | 57.10M |
| Operating Income | -47.09M | -50.73M | -54.33M | -53.71M | -53.42M |
| Income Before Tax | -47.43M | -52.22M | -56.94M | -56.11M | -55.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.43 | -52.22 | -56.94 | -56.11 | -55.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.43M | -52.22M | -56.94M | -56.11M | -55.60M |
| EBIT | -47.09M | -50.73M | -54.33M | -53.71M | -53.42M |
| EBITDA | -45.52M | -49.20M | -52.82M | -52.23M | -51.96M |
| EPS Basic | -0.02 | -0.03 | -0.03 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.02 | -0.03 | -0.03 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 8.66B | 8.17B | 7.67B | 7.53B | 7.38B |
| Average Diluted Shares Outstanding | 8.66B | 8.17B | 7.67B | 7.53B | 7.38B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |